Benzoxathiolone-Thiazolidinone Hybrids: A New Class in the Search for Anticancer Agents

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Cancer remains a leading global cause of death, necessitating urgent development of novel and targeted therapies.
• There is a critical need for more potent and specific anticancer treatments to improve patient outcomes.

Purpose of the Study:

• To synthesize novel benzoxathiolone-thiazolidinone hybrids.
• To evaluate the cytotoxic activity of these compounds against various human cancer cell lines.
• To identify potential lead compounds for anticancer drug development.

Main Methods:

• A series of 15 benzoxathiolone-thiazolidinone hybrids were synthesized using a multi-step approach.
• Cytotoxicity was assessed against five human cancer cell lines (gastric, melanoma, colon, tongue, leukemia) and one non-tumoral cell line.
• Molecular docking studies were performed to predict the binding interactions of active compounds.

Main Results:

• Two synthesized compounds demonstrated significant activity against the K562 leukemia cell line, with IC50 values of 4.0 μM and 5.3 μM.
• Docking analysis suggested these compounds may target the BCRABL1 kinase, implicated in chronic myeloid leukemia (CML).

Conclusions:

• The benzoxathiolone-thiazolidinone hybrids show promise as potential anticancer agents, particularly for leukemia.
• Further investigation into these compounds could lead to the development of new therapeutic strategies for CML.
• The identified compounds represent valuable starting points for optimizing anticancer drug candidates.